Leading the Way in Hemostaseology Research

Specialist in Hemostaseology Research

hVIVO, through its CRS network, is dedicated to advancing knowledge of blood clotting disorders and enhancing treatment options for patients around the world — combining decades of specialist experience with rigorous clinical trial infrastructure.

Schedule a Call

The Hemostaseology CRO

hVIVO, together with CRS, is at the forefront of cutting-edge research into blood coagulation mechanisms and pharmacological interventions. Our studies focus on uncovering critical insights that pave the way for improved treatment options and patient outcomes, spanning early-phase studies through to complex PK/PD investigations.

With decades of specialised experience in hemostaseology, hVIVO excels in areas such as single ascending dose (SAD), multiple ascending dose (MAD), investigations into drug and food interactions, bioavailability, and bioequivalence. Our deep scientific expertise supports sponsors in developing novel anticoagulants, antiplatelet therapies, and haemostatic agents from the earliest stages of clinical development.

  • Specialist expertise in hemostaseology across Phase I SAD, MAD, and PK/PD study designs
  • Investigations into drug and food interactions, bioavailability, and bioequivalence
  • Bleeding time assessments and bedside coagulation monitoring
  • Thrombocyte aggregation studies with rigorous safety compliance
  • Rapid patient and volunteer recruitment via an advanced enrolment database

Scientific & Technical Capabilities

Bleeding Time Assessments

  • Surgicutt® standardised incision time measurement

  • Template bleeding time testing

  • Capillary fragility evaluation

Bedside Coagulation Monitoring

  • Hemochron© activated partial thromboplastin time (aPTT)

  • Partial thromboplastin time with kaolin (PTT-K)

  • Prothrombin time (PT) / INR

  • Anti-Xa activity monitoring 

Platelet Function Testing

  • Thrombocyte aggregation studies (light transmission aggregometry)

  • PFA-100® platelet function analyser

  • Multiplate® impedance aggregometry

  • Flow cytometry for platelet activation markers

Coagulation Panel Testing

  • Fibrinogen levels (Clauss method)

  • D-dimer and FDP quantification

  • Factor activity assays (II, V, VII, VIII, IX, X, XI, XII)

  • Von Willebrand factor antigen and activity 

Indications Studied

  • Deep vein thrombosis (DVT) and pulmonary embolism (PE)
  • Atrial fibrillation (anticoagulation management)
  • Haemophilia A and B
  • Von Willebrand disease
  • Disseminated intravascular coagulation (DIC)
  • Immune thrombocytopenic purpura (ITP)
  • Heparin-induced thrombocytopenia (HIT)

Special Population and Patient Experience

Special Populations

  • Healthy volunteers for tolerability and PK studies

  • Patients with hereditary coagulation disorders

  • Renally and hepatically impaired patients

  • Elderly populations on anticoagulant therapy 

Patient Populations

  • Anticoagulant and antiplatelet therapy patients
  • Haemophilia patients
  • Thrombosis patients
  • Von Willebrand disease patients
  • Thrombocytopenia patients

Plan your next Hemostaseology Trial with hVIVO

Contact us today to learn how we can advance your clinical research in hemostaseology, ensuring patient safety and pioneering new treatment possibilities.

Enquire now

Our Tailored Solutions

As your trusted partner in hemostaseology, hVIVO maintains the highest standards of quality and precision in clinical research. Our specialised team ensures accurate and timely processing of a diverse range of samples, continually enhancing our medical diagnostic methods to provide tailored solutions that meet your specific clinical trial requirements.

Rapid Patient Recruitment

Our advanced volunteer and patient enrolment database enables swift recruitment across a wide range of hemostaseology studies — supporting fast, efficient study start-up and delivery across our CRS Berlin, Kiel, and Mannheim sites.

Advanced Assessment Techniques

Our capabilities include bleeding time assessments like Surgicutt®, bedside monitoring with Hemochron© for activated partial thromboplastin time (aPTT), partial thromboplastin time with kaolin, and thrombocyte aggregation studies. All assessments are performed in compliance with GCP and GLP standards, with rigorous safety monitoring maintained throughout every trial phase.

From first-in-human anticoagulant studies to complex multiple-dose investigations, hVIVO delivers the scientific rigour and operational excellence your hemostaseology programme demands.

German site T Frost with Patient Copyright by Julia Berlin_RAW__Y6A6418

End-to-End Drug Development Support

The hVIVO group provides end-to-end drug development support and has standalone and full-service offerings spanning regulatory strategy and submission support, CMC and PK/PD consultancy, project management, data management, and biostatistics services. With an established database of over 400,000 participants — including participants with cardiovascular, metabolic, and women's health-specific diseases — hVIVO can ensure your studies run seamlessly from start to finish, with dedicated recruitment, screening, and retention strategies tailored to female cohorts.

Rethinking Early‑Phase
Cardiometabolic Development:
From endpoints to execution

Read more in our e-book

Download now

FAQ

Get in touch with us

hVIVO, through CRS, provides a full range of hemostaseology research services including bleeding time assessments, coagulation monitoring with Hemochron©, platelet aggregation studies, and full coagulation panel testing.

Yes. With decades of specialised experience, CRS excels in single ascending dose (SAD), multiple ascending dose (MAD), and complex PK/PD studies in hemostaseology.

Available tools include Surgicutt®, Hemochron©, PFA-100®, Multiplate®, light transmission aggregometry, and full coagulation factor activity panels.

Key focus areas include deep vein thrombosis, haemophilia, von Willebrand disease, atrial fibrillation anticoagulation, thrombocytopenia, and DIC.

Yes. hVIVO supports early-phase hemostaseology studies from Phase I first-in-human studies through to Phase II proof-of-concept trials.

Plan your next trial with hVIVO

Find out how hVIVO can help you.

Enquire now